All In Biotech

Drug Trial Radar · NCT02957786

Cytisine Versus Varenicline for Smoking Cessation

RAUORA: Cytisine Versus Varenicline for Smoking Cessation

Last checked: Nov 20, 2026Latest source record: Aug 19, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 679 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

679

Actual

Start

Sep 18, 2017

Primary completion

Oct 10, 2019

Study completion Oct 10, 2019

Sponsor

Lead sponsor
University of Auckland, New ZealandAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Lakes District Health Board; Brunel University
First posted
Nov 8, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To evaluate the effectiveness, safety, and cost-effectiveness of cytisine plus behavioural support compared to varenicline plus behavioural support for smoking cessation, in indigenous Māori (or family of Māori) who smoke and are motivated to quit.

Conditions

  • Smoking Cessation

Interventions

  • CytisineDrug

    Cytisine tablets

  • Behavioural supportBehavioral

    Withdrawal-orientated cessation support

  • VareniclineDrug

    Varenicline tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Continuous abstinence from smokingTime frame: Six months post-quit date

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Institute for Health Innovation, University of Auckland

    Auckland, North Island, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.